SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, August 12, 2024, to review its financial results for the quarter ended June 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Monday, August 12, 2024, and prior to the conference call and webcast. To access the confere ...

SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company's common stock being $1.00 per share or greater for 10 consecutive trading sessions and that the matter is closed. "We are thrilled to ...

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01 a.m. Eastern Time on July 1, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Monday, July 1, 2024, and w ...

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 The reverse stock split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's stockholders authorized the reverse stock split at the Company's annual meeting of stockholders held on June 5, 2024. The reverse stock split will reduce the number of issued and outstanding shares of th ...

Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies for FSAD SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced the publication in Obstetrics & Gynecology, the official publi ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting Officer Conference Call Participants Douglas Tsao - H.C. Wainright Kemp Dolliver - Brookline Capital Markets Catherine Novack - Jones Research Operator Welcome to the conference call hosted by Daré Bioscience to review the company's First Quarter Financial Results and to provide the General Business Update. This ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incor ...

Financial Performance - Total revenue for Q1 2024 was $9.3 million, compared to $0 in Q1 2023[26] - Net loss for Q1 2024 was $6.76 million, compared to a net loss of $8.04 million in Q1 2023, reflecting an improvement of about 16%[26] - Loss per common share for Q1 2024 was $0.07, down from $0.09 in Q1 2023[26] - Royalty revenue of $9.3 million was recorded in Q1 2024, marking the first revenue generation for the company[26] Cash and Assets - Daré Bioscience reported cash and cash equivalents of $3.6 million as of March 31, 2024, and secured $22 million in non-dilutive royalty financing in April 2024[10] - Cash and cash equivalents decreased to $3.63 million as of March 31, 2024, from $10.48 million at the end of 2023[28] - Working capital deficit increased to $7.74 million as of March 31, 2024, compared to $2.94 million at the end of 2023[28] - Total assets decreased to $13.01 million as of March 31, 2024, from $21.28 million at the end of 2023[28] - Total stockholders' deficit increased to $10.99 million as of March 31, 2024, compared to $5.05 million at the end of 2023[28] Expenses - General and administrative expenses decreased to $2.7 million in Q1 2024 from $3.3 million in Q1 2023, primarily due to reduced corporate overhead[10] - Operating expenses decreased to $6.03 million in Q1 2024 from $8.38 million in Q1 2023, a reduction of approximately 28.2%[26] - Research and development (R&D) expenses were $3.3 million in Q1 2024, a 34% decrease from $5.0 million in Q1 2023, with expectations for lower R&D expenses in future quarters[10] - Research and development expenses were $3.33 million in Q1 2024, down from $5.02 million in Q1 2023, a decrease of approximately 33.7%[26] Product Development - The Phase 3 study of Ovaprene, a hormone-free monthly contraceptive, is currently recruiting patients across 18 sites in the U.S., supported by a central advertising campaign launched in March 2024[5] - Sildenafil Cream, 3.6%, is progressing toward a Phase 3 study, with the FDA expected to provide additional feedback on the study design in Q2 2024[7] - Daré's first FDA-approved product, XACIATO, is being commercialized by Organon and is available nationwide for the treatment of bacterial vaginosis in females aged 12 and older[2] - The company has received approximately $29.4 million under the DARE-LARC1 grant agreement to support nonclinical development of its investigational contraceptive[10] Company Vision and Commitment - Daré aims to deliver innovative treatments for women's health, focusing on first-in-category opportunities in contraception and sexual health[2] - The company is excited about the increased attention on women's health and is committed to advancing its late-stage candidates[2] - Daré's leadership has been recognized for contributions to innovation and advocacy in women's health, highlighting the company's commitment to this sector[20]

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representing 50% of the future payments otherwise payable to XOMA Transaction allows Daré to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal monthly contraceptive, and Sildenafil Cream, 3.6%, a potential first FDA-appr ...

Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it will receive a pay ...